XOMA Royalty Corporation (XOMA)
(Delayed Data from NSDQ)
$29.25 USD
-0.25 (-0.85%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $29.27 +0.02 (0.07%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Brokerage Reports
XOMA Royalty Corporation [XOMA]
Reports for Purchase
Showing records 61 - 80 ( 331 total )
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
2Q19 Results; Shopping Continues as Partners Advance Pipelines; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Novartis'' IL-1-Beta Oncology Play Continues to Gain In Visibility
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Novartis'' Increasing Support of CFZ533; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
1Q19 Results; Cash Flexibility to Source New Deals; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Acquires Royalty Rights to Five Hematology Assets from Aronora Inc.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Early Strategy Progress Continues; Follow the Numbers; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Awaiting Further Overall Pipeline Expansion; Novartis and Rezolute Push Forward
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Canakinumab Featured Prominently at Novartis R-D Day for NSCLC Opportunity; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Novartis Delay But Overall Shots on Goal Present Compelling Opportunity; Target Adjusted to $
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
So it Begins; XOMA Delivers First Validating Deal of New Strategy; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Q2 Financials- We Look to Potential Milestone Payments in 2018
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D